These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8286827)

  • 61. Treatment of chronic hepatitis C with interferon-alpha by monitoring the response according to viraemia.
    Bonetti P; Chemello L; Antona C; Breda A; Brosolo P; Casarin P; Crivellàro C; Donà G; Martinelli S; Rinaldi R; Zennaro V; Santonastaso M; Urban F; Pontisso P; Alberti A
    J Viral Hepat; 1997 Mar; 4(2):107-12. PubMed ID: 9097266
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment.
    Weiland O; Zhang YY; Widell A
    Scand J Infect Dis; 1993; 25(1):25-30. PubMed ID: 8384732
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
    Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
    Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recombinant alpha 2B interferon (IFN) in the treatment of chronic hepatitis C disease in thalassaemia major (TM).
    Wonke B; Donohue SM; Hoffbrand AV; Scheuer PJ; Brown D; Dusheiko G
    Bone Marrow Transplant; 1993; 12 Suppl 1():24-5. PubMed ID: 8397033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.
    Zeuzem S; Schmidt JM; Lee JH; Rüster B; Roth WK
    Hepatology; 1996 Feb; 23(2):366-71. PubMed ID: 8591865
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of chronic hepatitis C with interferon-alpha: sustained absence of hepatitis C virus RNA from serum after four courses of therapy.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Takahashi M
    J Int Med Res; 1995; 23(4):308-14. PubMed ID: 7589775
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment.
    Gil B; Qian C; Riezu-Boj JI; Civeira MP; Prieto J
    Hepatology; 1993 Nov; 18(5):1050-4. PubMed ID: 8225209
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha.
    Chemello L; Cavalletto L; Noventa F; Bonetti P; Casarin C; Bernardinello E; Pontisso P; Donada C; Casarin P; Belussi F
    J Viral Hepat; 1995; 2(2):91-6. PubMed ID: 7493303
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serological and salivary markers compared with biochemical markers for monitoring interferon treatment for hepatitis C virus infection.
    Roy KM; Bagg J; Bird GL; Spence E; Follett EA; Mills PR; Lau JY
    J Med Virol; 1995 Dec; 47(4):429-34. PubMed ID: 8636714
    [TBL] [Abstract][Full Text] [Related]  

  • 71. "Rebound" phenomenon of hepatitis C viremia after interferon therapy in "relapsed" patients with chronic hepatitis C.
    Hanada H; Hino K; Fujii K; Okazaki M; Okita K
    J Gastroenterol; 1995 Jun; 30(3):347-50. PubMed ID: 7544188
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.
    Gavier B; Martínez-González MA; Riezu-Boj JI; Lasarte JJ; Garcia N; Civeira MP; Prieto J
    Gastroenterology; 1997 Nov; 113(5):1647-53. PubMed ID: 9352868
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity.
    Enríquez J; Torras X; Miralles F; Martinez Cerezo FJ; Sancho Poch FJ; Buenestado J; Madoz P; Howe I; Vilardell F
    J Viral Hepat; 1995; 2(4):181-7. PubMed ID: 7489345
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers.
    Rumi MG; Santagostino E; Morfini M; Gringeri A; Tagariello G; Chistolini A; Pontisso P; Tagger A; Colombo M; Mannucci PM
    Blood; 1997 May; 89(10):3529-33. PubMed ID: 9160657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Outcome of the cases of chronic liver disease type C who exhibited long term response to interferon therapy; comparison of the cases with or without serum HCV-RNA].
    Tohyama H; Iwabuchi S; Takatori M
    Nihon Shokakibyo Gakkai Zasshi; 1996 Nov; 93(11):813-20. PubMed ID: 8953921
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy.
    Musset L; Ghillani P; Lunel F; Cacoub P; Cresta P; Frangeul L; Rosenheim M; Preud'homme JL
    Immunol Lett; 1997 Jan; 55(1):41-5. PubMed ID: 9093880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity.
    Serfaty L; Chazouillères O; Pawlotsky JM; Andreani T; Pellet C; Poupon R
    Gastroenterology; 1996 Jan; 110(1):291-5. PubMed ID: 8536870
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum hyaluronate levels predict responsiveness to interferon alpha therapy in patients with chronic hepatitis C.
    Matsunaga T; Kojima J; Inoue A; Matsumiya K
    Clin Chim Acta; 1994 Sep; 229(1-2):191-5. PubMed ID: 7988049
    [No Abstract]   [Full Text] [Related]  

  • 79. Duration of HCV infection as a predictor of nonresponse to interferon.
    Craxì A; Di Marco V; Cammà C; Almasio P; Magrin S
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):86S-92S. PubMed ID: 9011482
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cold activation of complement in sera from patients with persistent hepatitis C virus infection on interferon therapy.
    Aikawa T; Kimura I; Kojima M; Ueno C; Miyamoto K; Tango T; Tanaka N
    J Gastroenterol Hepatol; 1996 Apr; 11(4):341-6. PubMed ID: 8713700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.